NATALEE Data Shows Ribociclib Reduces Risk of Recurrence for

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.

Related Keywords

United States , American , Sebastian Kaulitzki , Denisea Yardley , Jeff Legos , Aimee Keegan , Sarah Cannon Research Institute , Breast Cancer Research Executive Committee , Global Head Of Oncology Development , European Medicines Agency , American Society Of Clinical Oncology , Novartis , Breast Cancer Research , Pharmacy Times , Clinical Oncology , Annual Meeting , Global Head , Oncology Development ,